The China International Import Expo is a world-class platform for global companies to cooperate on development, said Shi Wang, president of Sanofi Greater China, a regional subsidiary of France's largest healthcare company.

Sanofi values the development opportunities provided by the expo and plans to continue operating in the Chinese market, Xi told Xinhua in a recent interview.

He added that the company is committed to promoting innovation and exchange in the pharmaceutical and healthcare sectors between China and France, as well as promoting global industrial progress.

Xi said that since 2018, Sanofi has been one of the companies with an ideal presence at the exhibition, noting that the company has taken advantage of the platform to establish fruitful long-term partnerships.

He said the exhibition is a key link between Sanofi and the Chinese market, adding that the event not only provided the company with an opportunity to launch several innovative medicines in China, but also strengthened its presence in the market.

He explained that Sanofi gained broad support from the industry through the exhibition, allowing for faster delivery of new products to patients while expanding its partnerships with Chinese companies to enhance care for local patients.

This year marks the 60th anniversary of the establishment of diplomatic relations between China and France, and France is one of the guests of honor at the 7th China International Import Expo. China is Sanofi's second largest market globally, and it was one of the first multinational companies to enter the country after the reform and opening up.

Xi stressed China's strategic importance to Sanofi's future growth and its commitment to expanding domestic R&D efforts to bring Chinese innovations to global markets.

Xi said the pace of biomedical innovation in China is accelerating, providing great opportunities for Sanofi.